Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies.
Inflammation
; 43(2): 393-400, 2020 Apr.
Article
in En
| MEDLINE
| ID: mdl-31853715
Asthma is an immunoinflammatory disease characterized by bronchial hyper-reactivity to different external stimuli. New monoclonal target treatments have been developed, but few studies have investigated the role of regulatory T cells in severe asthma and the modulatory effect of biological therapy on regulatory T cell functions. Their dysfunction may contribute to the development and exacerbation of asthma. Here we review the recent literature on the potential immunological role of regulatory T cells in the pathogenesis of severe asthma. The analysis of the role of regulatory T cells was performed in terms of functions and their possible interactions with mechanisms of action of the novel treatment for severe asthma. In an era of biological therapies for severe asthma, little data is available on the potential effects of what could be a new therapy: monoclonal antibody targeting of regulatory T cell numbers and functions.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Severity of Illness Index
/
Drug Delivery Systems
/
T-Lymphocytes, Regulatory
/
Anti-Asthmatic Agents
/
Antibodies, Monoclonal, Humanized
Limits:
Humans
Language:
En
Journal:
Inflammation
Year:
2020
Document type:
Article
Affiliation country:
Italy
Country of publication:
United States